first designed a CLL1 CAR with specific killing efficacy on CLL1+ HL60 and THP1 cell lines and primary AML blasts in vitro, as well as exhibited anti-leukemia activity in an HL60-AML xenograft mouse model. Here, CLEC12A is linked to leukemia.